The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment - Ariceta Iraola, Gema (Hospital Universitari Vall d'Hebron) ; Dixon, B.P. (Renal Section. Department of Pediatrics. University of Colorado School of Medicine) ; Kim, S.H. (Department of Pediatrics. Pusan National University Children's Hospital) ; Kapur, G. (Faculty of Pediatric Sciences. Central Michigan University. Mount Pleasant) ; Mauch, T. (Department of Nephrology and Hypertension. Division of Pediatrics. University of Utah) ; Ortiz, S. (Clinical and Non-Clinical Pharmacology. Alexion Pharmaceuticals Inc.) ; Vallee, M. (Biostatistics. Alexion Pharmaceuticals Inc.) ; Denker, A.E. (Clinical Development. Alexion Pharmaceuticals Inc.) ; Kang, H.G. (Division of Pediatric Nephrology. Department of Pediatrics. Seoul National University College of Medicine) ; Greenbaum, L.A. (Division of Pediatric Nephrology. Emory University School of Medicine and Children's Healthcare of Atlanta) ; Lovell, H. ; Muff-Luett, M. ; Malone, K. ; Adeagbo, O. ; Wilkerson, A. ; Fraga Rodríguez, Gloria María (Institut d'Investigació Biomèdica Sant Pau) ; Sarri, S. ; Cheong, H.I. ; Ahn, Y.H. ; Han, K.H.
 
Comments (0) | Reviews (0)
Start a discussion about any aspect of this document.

 Subscribe to this discussion. You will then receive all new comments by email.

Add comment


Once logged in, authorized users can also attach files.
Note: you have not defined your nickname.
N/D will be displayed as the author of this comment.
          You can use some HTML tags: <a href>, <strong>, <blockquote>, <br />, <p>, <em>, <ul>, <li>, <b>, <i>